Personalized prediction of tumor response and cancer progression on prostate needle biopsy.


Journal Article

PURPOSE: To our knowledge in patients with prostate cancer there are no available tests except clinical variables to determine the likelihood of disease progression. We developed a patient specific, biology driven tool to predict outcome at diagnosis. We also investigated whether biopsy androgen receptor levels predict a durable response to therapy after secondary treatment. MATERIALS AND METHODS: We evaluated paraffin embedded prostate needle biopsy tissue from 1,027 patients with cT1c-T3 prostate cancer treated with surgery and followed a median of 8 years. Machine learning was done to integrate clinical data with biopsy quantitative biometric features. Multivariate models were constructed to predict disease progression with the C index to estimate performance. RESULTS: In a training set of 686 patients (total of 87 progression events) 3 clinical and 3 biopsy tissue characteristics were identified to predict clinical progression within 8 years after prostatectomy with 78% sensitivity, 69% specificity, a C index of 0.74 and a HR of 5.12. Validation in an independent cohort of 341 patients (total of 44 progression events) yielded 76% sensitivity, 64% specificity, a C index of 0.73 and a HR of 3.47. Increased androgen receptor in tumor cells in the biopsy highly significantly predicted resistance to therapy, ie androgen ablation with or without salvage radiotherapy, and clinical failure (p <0.0001). CONCLUSIONS: Morphometry reliably classifies Gleason pattern 3 tumors. When combined with biomarker data, it adds to the hematoxylin and eosin analysis, and prostate specific antigen values currently used to assess outcome at diagnosis. Biopsy androgen receptor levels predict the likelihood of a response to therapy after recurrence and may guide future treatment decisions.

Full Text

Duke Authors

Cited Authors

  • Donovan, MJ; Khan, FM; Fernandez, G; Mesa-Tejada, R; Sapir, M; Zubek, VB; Powell, D; Fogarasi, S; Vengrenyuk, Y; Teverovskiy, M; Segal, MR; Karnes, RJ; Gaffey, TA; Busch, C; Haggman, M; Hlavcak, P; Freedland, SJ; Vollmer, RT; Albertsen, P; Costa, J; Cordon-Cardo, C

Published Date

  • July 2009

Published In

Volume / Issue

  • 182 / 1

Start / End Page

  • 125 - 132

PubMed ID

  • 19450827

Pubmed Central ID

  • 19450827

Electronic International Standard Serial Number (EISSN)

  • 1527-3792

Digital Object Identifier (DOI)

  • 10.1016/j.juro.2009.02.135


  • eng

Conference Location

  • United States